Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis

Xing, Xiaojing; Li, Anqi; Li, Chang-Jiu

doi:10.1016/j.rmed.2020.106134

Cited by 53 publications

(41 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to previous studies, we found that anti‐SSA/Ro52 autoantibodies were the most commonly detected secondary antibodies 14 . These have also been shown previously to be associated with severe ILD 15,16 …”

Section: Discussionsupporting

confidence: 90%

“…14 These have also been shown previously to be associated with severe ILD. 15,16 Histopathology of skin lesions in patients with anti-MDA-5 has not been an emphasis in previous studies, although there have been reports of cutaneous vasculopathy being observed in the setting of MDA-5positive DM. 4 During our careful blinded review of 22 skin biopsies, we discovered that the presence of vasculopathy was associated with MDA-5 seropositivity; however, his feature was not consistently present.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical and histopathological features of adult patients with dermatomyositis and melanoma differentiation associated‐5 autoantibody seropositivity status, as determined by commercially available testing: a retrospective, single‐institution comparative cohort study

Shakshouk

Deschaine

Wetter

et al. 2021

Clin Experimental Derm

View full text Add to dashboard Cite

Background. Although melanoma differentiation associated (MDA)-5 autoantibodies have been widely explored in dermatomyositis (DM), most studies have relied on MDA-5 autoantibody testing performed in research settings, rather than the nowavailable commercial laboratory tests. Aim. To characterize the clinical and histopathological data in patients with DM and circulating MDA-5 autoantibodies, as defined by commercially available testing. Methods. This was a retrospective review of patients with DM who underwent MDA-5 antibody testing. All available skin biopsy slides were reviewed. Results. Cutaneous features more prevalent in MDA-5-positive DM included Raynaud phenomenon (RP) (P < 0.001), cutaneous ulcerations (P = 0.01), mechanic hands (P < 0.02), palmar papules (P < 0.01), oral ulcers (P = 0.024) and alopecia (P = 0.03). Joint and pulmonary involvement were more common in patients with MDA-5-positive DM (both P < 0.001) as was dysphagia (P < 0.01). Myopathy (P = 0.4) and malignancy (P = 0.34) were not statistically different between the cohorts. Vasculopathy was more common in MDA-5-positive DM (P < 0.01), while spongiosis was less common (P < 0.02). Conclusion. This study not only confirms some known associations between disease manifestations and MDA-5 autoantibody status, as determined by commercially available tests, but also identifies new associations, including RP and dysphagia.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Clinical and histopathological features of adult patients with dermatomyositis and melanoma differentiation associated‐5 autoantibody seropositivity status, as determined by commercially available testing: a retrospective, single‐institution comparative cohort study

Shakshouk

Deschaine

Wetter

et al. 2021

Clin Experimental Derm

View full text Add to dashboard Cite

show abstract

“…Several studies have confirmed that anti-Ro-52 antibody positivity is an independent risk factor for myositis and even in ILD associated with Sjogren's syndrome. [35][36][37][38] RP-ILD occurs more frequently in anti-ARS antibody positive patients who coexist with anti-Ro-52 antibody than in patients without anti-Ro-52 antibody. 39 In addition, the positive rate of MSAs was high in patients with isolated anti-Ro-52-ILD.…”

Section: Discussionmentioning

confidence: 99%

Risk Factors and Predictive Model for Dermatomyositis Associated with Rapidly Progressive Interstitial Lung Disease

Wang¹,

Tian²,

Liu³

et al. 2022

PGPM

View full text Add to dashboard Cite

Background Rapidly progressive interstitial lung disease (RP-ILD) is a significant complication that determines the prognosis of dermatomyositis (DM). Early RP-ILD diagnosis can improve screening and diagnostic efficiency and provide meaningful guidance to carry out early and aggressive treatment. Methods A retrospective screening of 284 patients with DM was performed. Clinical and laboratory characteristics of the patients were recorded. The risk factors of RP-ILD in DM patients were screened by logistic regression (LR) and machine learning methods, and the prediction models of RP-ILD were developed by machine learning methods, namely least absolute shrinkage and selection operator (LASSO), random forest (RF), and extreme gradient boosting (XGBoost). Results According to the result of univariate LR, disease duration is a protective factor for RP-ILD, and ESR, CRP, anti-Ro-52 antibody and anti-MDA5 antibody are risk factors for RP-ILD. The top 10 important variables of the 3 machine learning models were intersected to obtain common important variables, and there were 5 common important variables, namely disease duration, LDH, CRP, anti-Ro-52 antibody and anti-MDA5 antibody. The AUC of LASSO, RF and XGBoost test set were 0.661, 0.667 and 0.867, respectively. We further validated the performance of these three models on validation set, and the results showed that, the AUC of LASSO, RF and XGBoost were 0.764, 0.727 and 0.909, respectively. Based on the results of the models, XGBoost is the optimal model in this study. Conclusion Disease duration, LDH, CRP, anti-Ro-52 antibody and anti-MDA5 antibody are vital risk factors for RP-ILD in DM. The prediction model constructed using XGBoost can be used for risk identification and early intervention in DM patients with RP-ILD and practical application.

show abstract

“…In pSS, the occurrence of a lymphocytic interstitial pneumonitis (LIP) is rare, but this radiologic pattern should prompt a search for other manifestations of pSS if ILD is the first presenting manifestation (4). ILD is common in myositis, especially in patients with antibodies directed against different aminoacyl-tRNA synthetases, a group collectively called the antisynthetase syndrome (ASyS), but also those with anti-Ro52 antibodies (5,6). Anti-MDA5 antibodies are associated with clinically amyopathic dermatomyositis (CADM) which can present as a rapidly progressive ILD with high mortality despite aggressive immunosuppressive therapy (7).…”

Section: Frequently Encountered Ilds Associated With Systemic Diseasesmentioning

confidence: 99%

Editorial: Interstitial Lung Disease in the Context of Systemic Disease: Pathophysiology, Treatment and Outcomes

et al. 2021

View full text Add to dashboard Cite

Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis

Cited by 53 publications

References 21 publications

Clinical and histopathological features of adult patients with dermatomyositis and melanoma differentiation associated‐5 autoantibody seropositivity status, as determined by commercially available testing: a retrospective, single‐institution comparative cohort study

Clinical and histopathological features of adult patients with dermatomyositis and melanoma differentiation associated‐5 autoantibody seropositivity status, as determined by commercially available testing: a retrospective, single‐institution comparative cohort study

Risk Factors and Predictive Model for Dermatomyositis Associated with Rapidly Progressive Interstitial Lung Disease

Editorial: Interstitial Lung Disease in the Context of Systemic Disease: Pathophysiology, Treatment and Outcomes

Contact Info

Product

Resources

About